Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis

Data regarding immunogenicity of SARS-CoV-2 BNT162b2 vaccine in cystic fibrosis (CF) patients are limited. We prospectively measured total (TAbs-RBD; U/ml) and neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-receptor binding domain (RBD) protein in 33 CF patients and 66 healthy controls wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Michos, Athanasios, Filippatos, Filippos, Tatsi, Elizabeth-Barbara, Dellis, Charilaos, Efthymiou, Vasiliki, Zarkada, Ioanna, Troupi, Evgenia, Syriopoulou, Vasiliki, Loukou, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Cystic Fibrosis Society. Published by Elsevier B.V. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008191/
https://www.ncbi.nlm.nih.gov/pubmed/35461782
http://dx.doi.org/10.1016/j.jcf.2022.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008191/
https://www.ncbi.nlm.nih.gov/pubmed/35461782
http://dx.doi.org/10.1016/j.jcf.2022.04.004

Ejemplares similares